Why a single blood test might not tell the whole story
In short: Immunoassays are the workhorses of modern medicine, from pregnancy tests to anti-doping screens. They use the body's own defense system—antibodies—to hunt for specific molecules. But because they are so universal, they carry a unique risk: a single error can cascade into a chain of incorrect medical decisions.
Immunoassays (IA) function by leveraging the high specificity of antibodies to bind to target molecules called antigens. This biochemical 'lock and key' mechanism allows scientists to detect proteins, pathogens, or small molecules in complex fluids like serum or urine. While some assays use labels like enzymes or radioactive isotopes to produce a measurable signal, others are 'labeless,' detecting binding through physical changes like surface plasmon resonance or electrical resistance.
The technology has evolved significantly since its inception in the 1950s by Rosalyn Sussman Yalow and Solomon Berson. A major leap occurred in the late 1960s with the introduction of chemically linked enzymes, leading to the ubiquitous Enzyme-Linked Immunosorbent Assay (ELISA). Today, the industry is massive, with the commercial sector earning approximately US$17 billion in 2012. Modern variations include 'sandwich' assays, where an analyte is trapped between two antibodies, and multiplex platforms capable of detecting hundreds of targets in a single sample.
Despite their utility, immunoassays have a higher inherent analytical error rate than many other routine laboratory tests. A 2026 study in Türkiye highlighted this vulnerability, finding that for certain substances like opioids, immunoassays showed very low agreement with gold-standard confirmation methods (LC-MS/MS), producing notable false positives and negatives. Because these tests are so widely used, a single misleading result can trigger a 'cascade' of unnecessary investigations or incorrect diagnoses. Experts suggest moving toward a Bayesian reasoning paradigm, where lab results are integrated with clinical context rather than treated as deterministic facts.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Immunoassay
- Also: Comparison of Immunoassay Results near Cutoff Values with LC-MS/MS in Individuals with Substance Use Disorder Under Probation.
- Also: Averting Potential Misinterpretations and Diagnostic Misapplications of Misleading Laboratory Results.
To cite this card, link to https://intellectplus.co.uk/app/health-immunoassay.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Exercise & fitness · More in Health · Latest · A–Z · All topics
